Safety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: An observational, multicenter, open label, non-interventional study in Turkish patients

Basit Öğe Kaydı
dc.contributor.authorTozun, Nurdan
dc.contributor.authorSezgin, Orhan
dc.contributor.authorGulsen, Murat
dc.contributor.authorKacar, Sabite
dc.contributor.authorYenice, Necati
dc.contributor.authorYilmaz, Serif
dc.contributor.authorHulagu, Saadettin
dc.date.accessioned2024-04-24T17:24:36Z
dc.date.available2024-04-24T17:24:36Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/aims: Pegylated alfa interferon is the only immunomodulatory drug licensed for hepatitis B. We evaluated the safety and tolerability of peginterferon alfa-2a (40KD) in patients with chronic hepatitis B. Materials and Methods: A total of 113 chronic hepatitis B patients under peginterferon alfa-2a (40KD; 180 mu g/week) treatment were included in this multicenter, open label, non-interventional study, and 66 patients completed the follow-up period. Vital signs, physical examination and laboratory findings, concomitant medications, and adverse events were recorded. A Quality of Life questionnaire (Short Form-36) was performed twice, at the beginning and at the end of the study. Results: There was no significant difference between initial and last visits in terms of physical examination findings and Short Form-36 scores. A total of 27 adverse events were reported in 15 patients (22.7%), with most of them being mild in intensity (70.4%). The rates of the adverse events were similar in the monotherapy and combination therapy groups (peginterferon alfa-2a + lamivudine, peginterferon alfa-2a + adefovir or peginterferon alfa-2a + entecavir therapy groups), at 23.7% and 14.3%, respectively. The dosage of peginterferon had to be reduced in 3 patients (4.5%) due to thrombocytopenia. Overall patient compliance to treatment was detected as 85.9%. Conclusions: Based on the lack of serious adverse events and absence of impairment in Quality of Life, peginterferon alfa-2a (40KD, 180 mu g/week, subcutaneously) treatment for 48 weeks led to a high level of patient compliance and was associated with a high degree of safety and tolerability for the treatment of adult patients with chronic hepatitis B in real-life practice.en_US
dc.identifier.doi10.4318/tjg.2012.0410
dc.identifier.endpage559en_US
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue5en_US
dc.identifier.pmid23161301
dc.identifier.startpage552en_US
dc.identifier.trdizinid140927
dc.identifier.urihttps://doi.org/10.4318/tjg.2012.0410
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/140927
dc.identifier.urihttps://hdl.handle.net/11468/19757
dc.identifier.volume23en_US
dc.identifier.wosWOS:000311871900019
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPeginterferon Alfa-2aen_US
dc.subjectHbv Infectionen_US
dc.subjectSafetyen_US
dc.subjectPatient Complianceen_US
dc.subjectTolerabilityen_US
dc.subjectReal-Life Practiceen_US
dc.titleSafety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: An observational, multicenter, open label, non-interventional study in Turkish patientsen_US
dc.titleSafety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: An observational, multicenter, open label, non-interventional study in Turkish patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu